Loading
REGOBONE showed that the tablet regorafenib delayed progression of osteosarcoma that had come back after chemotherapy, giving one of the few randomised results in relapsed bone cancer.
REGOBONE was a French placebo-controlled randomised phase 2 trial run as parallel cohorts by histology in patients aged 10 or older with metastatic bone sarcoma progressing after standard chemotherapy. Patients received regorafenib, a multikinase inhibitor, or placebo with crossover allowed at progression. The primary endpoint was progression-free survival at eight weeks in the osteosarcoma cohort.
The osteosarcoma cohort met its endpoint, with more patients progression-free at eight weeks and longer median progression-free survival on regorafenib, matching the American SARC024 trial reported at the same time. The Ewing sarcoma cohort also favoured regorafenib, and the chondrosarcoma cohort suggested activity in conventional and dedifferentiated tumours; chordoma results were reported separately. Regorafenib is used at relapse on this evidence though it has no formal approval in bone sarcoma.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
163 enrolled.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bayer, Regorafenib, Anti-angiogenic therapy, Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
Shares Ewing sarcoma, Osteosarcoma, Anti-angiogenic therapy, Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
Shares Ewing sarcoma, Osteosarcoma, Sarcomas (soft tissue, bone, GIST) and the tag subtype-trials.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Sarcomas (soft tissue, bone, GIST), Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Bayer and the tag subtype-trials.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/